(Q37018333)

17 August 2017

1 reference

title

Significance and impact of bisphosphonate-induced acute phase responses (English)

1 reference

17 August 2017

Karin Olson

1

1 reference

PubMed ID

18045781

17 August 2017

Catherine Van Poznak

series ordinal

2

1 reference

17 August 2017

1 December 2007

1 reference

Journal of Oncology Pharmacy Practice

17 August 2017

1 reference

17 August 2017

13

1 reference

17 August 2017

4

1 reference

17 August 2017

223-229

1 reference

Recent advances in understanding the mechanism of action of bisphosphonates

17 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Molecular mechanisms of action of bisphosphonates: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Bisphosphonates: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Bisphosphonate treatment recommendations for oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Breast cancer: bisphosphonate therapy for metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

The systemic reaction during inflammation: the acute-phase proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

C-reactive protein: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Adverse effects of bisphosphonates. A comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Bisphosphonates for malignancy-related bone disease: current status, future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Renal safety of ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Goals of treatment for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Approaches to managing bone metastases from breast cancer: the role of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Bisphosphonates and metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207080806

21 January 2018

Identifiers

DOI

10.1177/1078155207080806

1 reference

release_zjvxwq55vrf7bcl5zkgl3ofafe

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zjvxwq55vrf7bcl5zkgl3ofafe

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18045781

1 reference

PubMed ID

18045781